Appendix 3H – Notification of cessation of securities 2024 Announcements . Financial . News . Regulatory 04.04.2024
Appendix 3C – Update – Notification of buy-back 2024 Announcements . Financial . News . Regulatory 18.03.2024
SCENESSE® efficacy in vitiligo: new case presented at AAD 2024 Announcements . Clinical . News . Regulatory 11.03.2024
SCENESSE® Presented at American Academy of Dermatology 2024 Announcements . News . Regulatory 08.03.2024
Notice of ceasing to be a substantial holder 2024 Announcements . Financial . News . Regulatory 05.03.2024
SCENESSE® provides photoprotection, improves QoL in variegate porphyria 2024 Announcements . Clinical . News . Regulatory 04.03.2024
Appendix 3Z – Final Director’s Interest Notice 2024 Announcements . Financial . News . Regulatory 27.02.2024
CLINUVEL Delivers Increased Revenues, Solid Earnings in December 2023 Half Year 2024 Announcements . Financial . News . Regulatory 22.02.2024
Appendix 4D Half year ended 31 December 2023 2024 Announcements . Financial . News . Regulatory 22.02.2024
Notice of change of interests of substantial holder 2024 Announcements . Financial . News . Regulatory 31.01.2024